ZoBio of Leiden has been selected by pharmaceutical company UCB to provide ligand discovery services for fragment-based drug discovery.
ZoBio of Leiden said pharmaceutical company UCB has selected it to provide ligand discovery services for fragment-based drug discovery. Under the agreement ZoBio will immobilise UCB targets and carry out ligand screening using its proprietary Target sNMR Screening (TINS) technology.
Using its TINS technology, ZoBio can rapidly generate high affinity, high specificity lead compounds with optimal drug-like properties. The company was founded in 2004 as a spinout from Leiden University
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
